Report Highlights
Over the last decade, biomarker research has become one of the essential aspects not only of the in vitro diagnostics industry but an important component of the drug discovery and development process. Moreover, with the growing trend in personalized medicine and companion diagnostics, the use of biomarkers is becoming obligatory in management of certain diseases, such as cancer drug regimen.
Report Includes
- 43 data tables and 42 additional tables
- An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including detailed analysis of deals structure and their potential values
- Information about significant players in this field of study, trends and obstacles, and other information affecting biomarker market development
- Review of business terms and conditions of deals in the biomarker market, with focus on major trends in biomarker deal making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
- Essential information to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
- Identification of the main elements in licensing, acquisitions and partnership deals in the biomarker industry
- Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis et al.
- Details of various types of biomarkers deals and milestone payments and their value in different deals
- Examination of competitive landscape and detailed profiles of major companies developing biomarkers, including bioMérieux SA, IntegraGen SA, MDxHealth, Myriad Genetics, Protagen AG and Qiagen
Report Scope
This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U. S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.
Analyst Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.
Related Reports
MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets
The global market for microRNA (miRNA) research tools is estimated to increase from $664.2 million in 2023 to $883.0 million by 2028, at a compound annual growth rate (CAGR) of 5.9% from 2023 through 2028.
Renal Biomarkers: Technologies and Global Markets
The global market for renal biomarkers is estimated to increase from $1.2 billion in 2022 to reach $1.7 billion by 2027, at a compound annual growth rate (CAGR) of 7.6% from 2022 through 2027.
Molecular Diagnostics: Technologies and Global Markets
The global molecular diagnostics market should reach $42.6 billion by 2026 from $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 19.3% for the forecast period of 2021 to 2026.
2021 Biotechnology Research Review
BCC Research Market Report says bioinformatics should grow from $16.1 billion in 2020 to $24.1 billion by 2025 with a compound annual growth rate (CAGR) of 8.4%.
Recent Reports
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More